Polio vaccine in several other African nations without necessary information, which epidemiologists believe is due to refusals by certain local populations to allow their children to receive the polio vaccine. The Salk vaccine, IPV, is based on three wild, virulent reference strains, Mahoney (type 1 poliovirus), MEF-1 (type 2 poliovirus), and Saukett (type 3 poliovirus), grown in a type of monkey kidney tissue culture (Vero cell line), which are then inactivated with formalin. The injected Salk vaccine confers IgG-mediated immunity in the bloodstream, which prevents polio infection from progressing to viremia and protects the motor neurons, thus eliminating the risk of bulbar
The Immune Response Corporation The Immune Response Corporation The Immune Response Corporation (IRC), founded by Jonas Salk and Kevin Kimberlin and based in Carlsbad, California, pioneered immunotherapeutic products. Francis Crick once said about Salk, “Few have made one discovery that has benefited humanity so greatly. Jonas was a man who, right to his last day, was actively in pursuit of another.” That pursuit was The Immune Response Corporation. Kimberlin “asked Salk to become lead scientific advisor for a new biotech company specializing in ‘anti-idiotypes,’ a novel vaccine technology.” Salk called the proposal “liberating.” The management team included CEO Jim Glavin, former CEO of Genetic